Masimo

Masimo reports positive data from SafetyNet study in Covid-19 patients

Masimo has reported positive data from a two-part retrospective study of SafetyNet, the remote patient management and telehealth solution.

Masimo SafetyNet is a scalable, secure, cloud-based patient management platform designed to help healthcare providers manage patient care remotely.

It includes clinical-grade sampling and continuous measurements, remote patient monitoring and digital care pathways.

Using the company’s tetherless Masimo Radius PPG SET pulse oximetry and a smartphone application, the system continuously sends home-based patient monitoring data to clinicians.

The study aimed to assess the impact of Remote Patient Monitoring (RPM) using SafetyNet on hospital stay time (LOS) in Covid-19 patients.

It was performed by Dr. Hemali Patel and colleagues from the University of Colorado in collaboration with UC Health (UCH), located in Aurora, Colorado, USA.

The findings, published in Telemedicine and e-Health, showed that RPM with Masimo SafetyNet reduced hospitalization for Covid-19 patients.

The study also showed a significant association between shorter hospital stays and patients discharged with the new RPM device and without oxygen at home.

The researchers concluded that home telemonitoring of Covid-19 patients after discharge could be a safe tool to help reduce the average length of hospital stay and create more capacity for beds in hospitals.

They implemented an RPM feasibility program with SafetyNet (Phase I) on UCH during the first Covid-19 peak, from March to June 2020.

During the second peak (Phase II), from October 2020 to February last year, they redeployed the device.

The researchers remotely monitored heart rate, plethysmographic respiratory rate (Masimo RRp), and oxygen saturation (SpO₂) using Masimo SafetyNet with Radius PPG.

The data was sent through the company’s HIPAA-compliant secure cloud service.

A total of 923 patients were enrolled in Phase I, of whom 78 were discharged with SafetyNet and 845 without.

Phase II enrolled 1,056 patients. 125 were released with SafetyNet and 931 without.

The study compared discharged patients with and without SafetyNet using a two-to-one matched case-control design.

The patients were matched at each stage depending on age, gender, Charlson comorbidity index, and limited English proficiency.

Related companies



Leave a Comment

Your email address will not be published.